Technical weakness persists as BridgeBio Pharma stock trades near weekly lows

Traders Union
All News
Companies
BridgeBio Pharma slides 1.66% today

Highlights

BBIO trades below key moving averages, signaling near-term and potential long-term bearish pressure amid continued selling.
Momentum indicators confirm prevailing weakness, with strong sell signals and minimal trend strength, indicating further downside risk.
BBIO is expected to consolidate between $66.00 and $67.80 next week, with a downside bias and little probability of upward breakout.

Downside risk builds as price breaches key averages and Ichimoku resistance

BBIO is currently trading at $66.27, below its MA-20 ($67.15), MA-50 ($69.67), and MA-200 ($67.55), indicating short- and medium-term downside pressure, while the long-term trend may be at risk of turning bearish. The Ichimoku Kijun level on D1 is $67.11, acting as immediate resistance above the current price. Near-term support is identified at MA-200 ($67.55), while key support lies at MA-100 ($70.42). Near-term resistance is set by the Kijun ($67.11), with key resistance at MA-50 ($69.67).

Weak momentum persists as bearish signals and volatility reinforce decline

Momentum indicators on D1 show prevailing weakness. MACD signals a strong sell, with ADX at a low 10.65, suggesting the current trend lacks strength. RSI (45.42) and Stoch RSI (55.45, strong sell) both indicate further room to the downside, while CCI holds neutral. BBP on D1 registers as overbought with a value of 1.52, yet fast intraday frames flag a shift toward seller dominance. The Awesome Oscillator also aligns with a bearish tone. In today's session, BBIO declined 1.66% from the previous close, underscoring near-term selling. Over the week, BBIO has slipped $0.53 (0.79%), down from a prev_week_close of $66.80, and is currently trading in the lower part of its weekly range as volatility stands at 4.52%. This steady weekly decline from the high is consistent with momentum weakness.

Bearish consolidation likely as low rebound odds cap upside potential

For the coming week, we expect BBIO to trade between $66.00 and $67.80, reflecting the typical weekly volatility and capturing a sideways-to-weak price corridor well above its 52-week low ($40.19) but considerably below its 52-week high ($84.94). The probability of a price increase is very low (less than 20%), as only ADX-W1 gives a buy signal while RSI-W1 and MACD-W1 remain weak; a decline is therefore much more likely. The baseline scenario is for BBIO to remain range-bound between $66.00 (support) and $67.80 (resistance). A bullish scenario would require a clear break above $67.80, potentially targeting MA-50 resistance, while a bearish move below $66.00 could trigger a test of lower supports. Overall, the outlook favors continued consolidation with a bearish tilt unless there is a notable momentum reversal.

Loading...

The tweet was deleted by the author.

But we saved everything 🙂.

Earlier, analysts noted that BridgeBio Pharma maintained a broadly bearish technical setup with prevailing downside risks. As sentiment and conditions evolve, traders should closely monitor for shifts in momentum or breakout signals that could define the next directional move.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.